Login to Access Video or Poster Abstract: MP44-09
Sources of Funding: none

Introduction

Germline copy number polymorphisms (CNPs) are expected to affect various diseases including human malignancies, but the significance of CNPs in non-muscle invasive bladder cancer (NMIBC) remains unclear. PCSK6 is reported to regulate proliferation and tumor progression in breast and prostate cancer, and affect sodium homeostasis. The purpose of this study is to determine the prognostic value of CNPs for NMIBC. To our knowledge, this is the first report to confirm CNPs as a potential biomarker for assessing the prognosis of NMIBC.

Methods

Array comparative genomic hybridization (CGH) was performed to search for candidate CNPs related to NMIBC susceptibility. Next, quantitative real-time polymerase chain reaction was carried out to evaluate for CNPs related to patient's outcome in 190 NMIBC.

Results

Eleven CNPs were associated with NMIBC risk in array CGH. FAM81A and PCSK6 copy number according to those CNPs examined showed significant relationship with recurrence and disease progression in NMIBC. Patients with pT1 stage had significantly lower PCSK6 copy number than those with pTa (P = 0.0258). Interestingly, patients with lower PCSK6 copy number had significantly higher sodium levels in the blood than those with higher PCSK6 copy number (P = 0.0144). Univariate Cox proportional hazards regression analysis showed that tumor grade (P = 0.0073), pT stage (P = 0.0086), Cytology (P = 0.0045), FAM81A (P = 0.0173), and PCSK6 (P = 0.0011) copy number had a significant effect on progression-free survival. In multivariate analyses, PCSK6 copy number was an independent prognostic factor for progression-free survival (P = 0.0380, risk ratio 2.25, 95% confidence interval 1.05-5.03).

Conclusions

These data suggest that PCSK6 CNP is potentially a new tumor marker for estimating the prognosis of NMIBC.

Funding

none